Antifibrotic-optimized new drug candidate 'NP-011' aims to enter phase 1 clinical trial in mid-2021 for liver disease and heart disease
Nexel announced on the 22nd that it has obtained a US patent for “NP-011,” which is being developed as a treatment for liver fibrotic diseases.
'NP-011' is a new drug candidate that optimizes the anti-fibrotic effect of the 'MFG-E8' protein discovered from secreted substances from human stem cells-derived hepatocytes and the patent for 'NP-011' has already been registered in Korea and Japan in 2019.
Dr. Han Choong-seong, CEO of Nexel, commented, "Following the registration of patents for NP-011, a new drug candidate for fibrosis treatment, in Korea and Japan, we have secured a foothold for NP-011's global advance through the acquisition of US substance patents."
Fibrotic disease is a disease in which excessive fibrotic tissue is formed in organs through a chronic inflammatory reaction. As the tissue becomes hardened, the function of the organ decreases, leading to death. Despite the risk of these diseases, only a few symptom relievers with limited effectiveness are currently being developed, and no underlying treatment is known.
Nexel has recently expanded an indication of NP-011 to various treatment areas such as liver fibrosis, alcoholic hepatitis and myocardial infarction, and obtained the related patents. Among the pipelines under development, the company is aiming to enter phase 1 of mid-2021 and explained, primarily for liver disease and heart disease.
Meanwhile, Nexel is preparing to list on the KOSDAQ by selecting NH Investment & Securities as its host company.